Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration
Rheumatoid Arthritis
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring methotrexate injection, subcutaneous, autoinjector
Eligibility Criteria
Inclusion Criteria:
- Male or female >18 years of age with diagnosed Rheumatoid Arthritis(RA).
Exclusion Criteria:
- Chronic or acute renal disease
- Any other clinically significant disease or disorder which, in the opinion of the investigator, might put the subject at risk
Sites / Locations
- Altoona Center for Clinical Research
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
10mg Methotrexate (MTX) Group
15mg Methotrexate (MTX) Group
20mg Methotrexate (MTX) Group
25mg Methotrexate (MTX) Group
Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection